MX2010004211A - Composicion oftalmica que comprende una prostaglandina. - Google Patents

Composicion oftalmica que comprende una prostaglandina.

Info

Publication number
MX2010004211A
MX2010004211A MX2010004211A MX2010004211A MX2010004211A MX 2010004211 A MX2010004211 A MX 2010004211A MX 2010004211 A MX2010004211 A MX 2010004211A MX 2010004211 A MX2010004211 A MX 2010004211A MX 2010004211 A MX2010004211 A MX 2010004211A
Authority
MX
Mexico
Prior art keywords
prostaglandin
ophthalmic composition
salts
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
MX2010004211A
Other languages
English (en)
Inventor
Subhas Balaram Bhowmick
Ajay Jaysingh Khopade
Arindam Halder
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2010004211A publication Critical patent/MX2010004211A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica adecuada para uso oftálmico que comprende uno o más derivados de prostaglandina o sales, una cantidad estabilizadora de hidroxiestearato de polietilen glicol y un vehículo farmacéuticamente aceptable.
MX2010004211A 2007-10-16 2008-10-15 Composicion oftalmica que comprende una prostaglandina. MX2010004211A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2061MU2007 2007-10-16
PCT/IN2008/000671 WO2009084021A2 (en) 2007-10-16 2008-10-15 Novel ophthalmic compositions

Publications (1)

Publication Number Publication Date
MX2010004211A true MX2010004211A (es) 2010-06-30

Family

ID=40824837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004211A MX2010004211A (es) 2007-10-16 2008-10-15 Composicion oftalmica que comprende una prostaglandina.

Country Status (18)

Country Link
US (2) US9629852B2 (es)
EP (1) EP2197449A4 (es)
JP (1) JP5646331B2 (es)
KR (1) KR101510185B1 (es)
CN (1) CN101835473B (es)
AU (1) AU2008344909B2 (es)
BR (1) BRPI0818459A2 (es)
CA (1) CA2702478C (es)
CO (1) CO6270384A2 (es)
EA (1) EA201070483A1 (es)
EC (1) ECSP10010167A (es)
IL (1) IL205095A0 (es)
MX (1) MX2010004211A (es)
NZ (1) NZ584555A (es)
SG (1) SG185273A1 (es)
UA (1) UA100393C2 (es)
WO (1) WO2009084021A2 (es)
ZA (1) ZA201002615B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482851C2 (ru) * 2009-02-20 2013-05-27 Микро Лабс Лимитед Хранение стабильного продукта простагландина
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9907826B2 (en) * 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
CN105012231A (zh) * 2014-04-30 2015-11-04 四川科伦药物研究院有限公司 一种包含PGF2α衍生物的稳定性良好的眼用制剂及其制备方法
JP7173870B2 (ja) * 2016-12-28 2022-11-16 中外製薬株式会社 化合物の膜透過性を改善するための自己乳化型製剤
SG11201911750RA (en) * 2017-06-08 2020-01-30 Eye Therapies Llc Low-dose brimonidine combinations and uses thereof
CN110237031B (zh) 2018-07-12 2022-02-11 尼科斯股份有限公司 包含释放一氧化氮的前列酰胺的眼用组合物
CN114245737A (zh) * 2019-06-11 2022-03-25 司斐股份有限公司 微乳剂组合物
US11400100B2 (en) 2019-12-11 2022-08-02 Somerset Therapeutics, Llc. Effective benzalkonium chloride-free bimatoprost ophthalmic compositions
KR20230131822A (ko) * 2020-10-13 2023-09-14 렌즈 테라퓨틱스 인코포레이티드 저장 안정성 안약을 위한 조성물 및 방법
JP2022120120A (ja) * 2022-06-13 2022-08-17 東亜薬品株式会社 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
ATE285795T1 (de) * 1998-07-14 2005-01-15 Alcon Mfg Ltd Polypropylenbasierte behälter für prostaglandin- enthaltende produkte
KR100350179B1 (ko) 1998-09-23 2002-08-27 구주제약주식회사 Ｓｅｄｄｓ로 제제화한 발기부전치료용 주입액제
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
JP4092507B2 (ja) * 2003-07-31 2008-05-28 参天製薬株式会社 プロスタグランジン含有製品
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
CA2578176C (en) * 2004-11-09 2013-09-24 Novagali Pharma Sa Ophthalmic emulsions containing an immunosuppressive agent
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
CN104224704A (zh) * 2006-03-13 2014-12-24 株式会社·R-技术上野 水性组合物
WO2008074885A2 (en) * 2006-12-21 2008-06-26 Novagali Pharma Sa Process for manufacturing ophthalmic oil-in-water emulsions
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur

Also Published As

Publication number Publication date
IL205095A0 (en) 2010-11-30
WO2009084021A2 (en) 2009-07-09
CN101835473B (zh) 2012-12-05
AU2008344909A1 (en) 2009-07-09
CN101835473A (zh) 2010-09-15
KR101510185B1 (ko) 2015-04-10
US20100137432A1 (en) 2010-06-03
UA100393C2 (ru) 2012-12-25
US9629852B2 (en) 2017-04-25
CA2702478C (en) 2014-12-09
SG185273A1 (en) 2012-11-29
KR20100087107A (ko) 2010-08-03
ZA201002615B (en) 2010-12-29
AU2008344909B2 (en) 2013-06-06
EA201070483A1 (ru) 2010-10-29
WO2009084021A3 (en) 2009-12-03
EP2197449A2 (en) 2010-06-23
JP5646331B2 (ja) 2014-12-24
CO6270384A2 (es) 2011-04-20
EP2197449A4 (en) 2013-10-09
BRPI0818459A2 (pt) 2015-04-14
US20150290216A1 (en) 2015-10-15
ECSP10010167A (es) 2010-06-29
NZ584555A (en) 2012-03-30
US9539262B2 (en) 2017-01-10
JP2011508724A (ja) 2011-03-17
CA2702478A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
MX2010004211A (es) Composicion oftalmica que comprende una prostaglandina.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
GEP201606555B (en) Compounds and compositions for modulating egfr activity
UA94964C2 (ru) Производные 5-замещенного хиназолинона, композиция, которая их содержит, и их применение
WO2013163244A8 (en) Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
IN2012DN01233A (es)
MX2009003958A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso.
EA021377B9 (ru) Модуляторы толл-подобных рецепторов
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
MX2009012595A (es) Derivados de espiroindolinona.
IL205354A0 (en) Spiroindolinone derivatives
MX339570B (es) Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
WO2010049449A3 (en) Novel salts of sunitinib
WO2009140341A3 (en) Atorvastatin compositions
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
TN2012000105A1 (en) Spirolactam derivatives and uses of same

Legal Events

Date Code Title Description
FG Grant or registration